
GlycoMimetics Inc (CBIO) Stock Forecast & Price Target
GlycoMimetics Inc (CBIO) Analyst Ratings
Bulls say
Crescent Biopharma Inc. has demonstrated a significant positive outlook due to the promising results from the HARMONi-A OS trial, which confirms that their modality can achieve meaningful survival advantages in a patient population where Keytruda is not the standard of care. The successful outcomes of the Phase 3 trial indicate that CR-001, a bispecific antibody, is capable of translating robust progression-free survival (PFS) benefits into overall survival advantages, positioning it favorably against competitive therapies. Furthermore, the lucrative partnership arrangements for similar drug classes suggest strong market potential and commercial opportunities for Crescent Biopharma, enhancing the company's financial prospects as it advances its drug pipeline.
Bears say
Crescent Biopharma faces significant risks that contribute to a negative outlook on its stock, particularly the potential for adverse events related to its lead program, CR-001, and its progression through clinical trials. Additionally, there are concerns about the possibility that CR-001 may demonstrate a notably inferior efficacy profile compared to competing therapies, which could hinder its success in the market. The existence of a valuation gap further complicates the financial outlook, indicating potential challenges in achieving expected revenue milestones.
This aggregate rating is based on analysts' research of GlycoMimetics Inc and is not a guaranteed prediction by Public.com or investment advice.
GlycoMimetics Inc (CBIO) Analyst Forecast & Price Prediction
Start investing in GlycoMimetics Inc (CBIO)
Order type
Buy in
Order amount
Est. shares
0 shares